PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis

被引：0
|
作者：
Schettini, F. [1 ]
Pascual, T. [1 ]
Chic, N. [1 ]
Conte, B. [2 ]
Martinez, O. [1 ]
Adamo, B. [1 ]
Vidal, M. [1 ]
Munoz, M. [1 ]
Fernandez-Martinez, A. [3 ]
Griguolo, G. [4 ]
Guarneri, V. [4 ]
Conte, P. F. [4 ]
De Placido, S. [5 ]
Carey, L. [6 ]
Perou, C. M. [7 ]
Prat, A. [1 ]
机构：
[1] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
[2] Univ Genoa, Osped Policlin San Martino, Med Oncol, Genoa, Italy
[3] Univ N Carolina, Med, Chapel Hill, NC 27515 USA
[4] Ist Oncol Veneto IRCCS, Surg Oncol & Gastroenterol, Padua, Italy
[5] Azienda Univ Osped Federico II, Clin Med & Surg, Naples, Italy
[6] UNC, Lineberger Canc Ctr, Med, Div Hematol Oncol, Chapel Hill, NC USA
[7] UNC, Lineberger Canc Ctr, Genet, Chapel Hill, NC USA
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
248P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Variation in pathological complete response in HER2-positive breast cancers with intrinsic subtypes assessed by PAM50 testing: secondary analysis from NSABP B-41 trial
    Arun Kumar Goel
    Vaishali Zamre
    Shreebha Hari
    Breast Cancer Research and Treatment, 2020, 183 : 489 - 490
  • [22] Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
    Hohmann, L.
    Sigurjonsdottir, K.
    Bosch, A.
    Nacer, D. F.
    Veerla, S.
    Hakkinen, J.
    Vallon-Christersson, J.
    Borg, A.
    Memari, Y.
    Davies, H.
    Nik-Zainal, S.
    Staaf, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S310 - S311
  • [23] The role of the phosphatase and tensin homolog status in predicting pathological complete response to neoadjuvant anti-HER2 therapies in HER2-positive primary breast cancer A meta-analysis
    Zhang, Chi
    Guo, Ying
    Li, Jiyu
    Tian, Xingsong
    Duan, Xuening
    MEDICINE, 2019, 98 (05)
  • [24] Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
    Schettini, Francesco
    Chic, Nuria
    Braso-Maristany, Fara
    Pare, Laia
    Pascual, Tomas
    Conte, Benedetta
    Martinez-Saez, Olga
    Adamo, Barbara
    Vidal, Maria
    Barnadas, Esther
    Fernandez-Martinez, Aranzazu
    Gonzalez-Farre, Blanca
    Sanfeliu, Esther
    Cejalvo, Juan Miguel
    Perrone, Giuseppe
    Sabarese, Giovanna
    Zalfa, Francesca
    Peg, Vicente
    Fasani, Roberta
    Villagrasa, Patricia
    Gavila, Joaquin
    Barrios, Carlos H.
    Lluch, Ana
    Martin, Miguel
    Locci, Mariavittoria
    De Placido, Sabino
    Prat, Aleix
    NPJ BREAST CANCER, 2021, 7 (01)
  • [25] Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
    Francesco Schettini
    Nuria Chic
    Fara Brasó-Maristany
    Laia Paré
    Tomás Pascual
    Benedetta Conte
    Olga Martínez-Sáez
    Barbara Adamo
    Maria Vidal
    Esther Barnadas
    Aranzazu Fernández-Martinez
    Blanca González-Farre
    Esther Sanfeliu
    Juan Miguel Cejalvo
    Giuseppe Perrone
    Giovanna Sabarese
    Francesca Zalfa
    Vicente Peg
    Roberta Fasani
    Patricia Villagrasa
    Joaquín Gavilá
    Carlos H. Barrios
    Ana Lluch
    Miguel Martín
    Mariavittoria Locci
    Sabino De Placido
    Aleix Prat
    npj Breast Cancer, 7
  • [26] Clinicopathological Factors Predicting Pathological Complete Response to Neoadjuvant Anti-HER2 Therapy in HER2-Positive Breast Cancer
    Jung, Youn Joo
    Lee, Seungju
    Kang, Seok Kyeong
    Kim, Jee Yeon
    Choo, Ki Seok
    Nam, Kyung Jin
    Joo, Ji Hyeon
    Kim, Jae Joon
    Kim, Hyun Yul
    ONCOLOGY, 2024,
  • [27] Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
    Canino, Fabio
    Piacentini, Federico
    Omarini, Claudia
    Toss, Angela
    Barbolini, Monica
    Vici, Patrizia
    Dominici, Massimo
    Moscetti, Luca
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [28] Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis
    Niikura, Naoki
    Shimomura, Akihiko
    Fukatsu, Yumi
    Sawaki, Masataka
    Ogiya, Rin
    Yasojima, Hiroyuki
    Fujisawa, Tomomi
    Yamamoto, Mitsugu
    Tsuneizumi, Michiko
    Kitani, Akira
    Watanabe, Junichiro
    Matsui, Akira
    Takahashi, Yuko
    Takashima, Seiki
    Shien, Tadatoshi
    Tamura, Kenji
    Saji, Shigehira
    Masuda, Norikazu
    Tokuda, Yutaka
    Iwata, Hhiroji
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (01) : 81 - 87
  • [29] Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis
    Naoki Niikura
    Akihiko Shimomura
    Yumi Fukatsu
    Masataka Sawaki
    Rin Ogiya
    Hiroyuki Yasojima
    Tomomi Fujisawa
    Mitsugu Yamamoto
    Michiko Tsuneizumi
    Akira Kitani
    Junichiro Watanabe
    Akira Matsui
    Yuko Takahashi
    Seiki Takashima
    Tadatoshi Shien
    Kenji Tamura
    Shigehira Saji
    Norikazu Masuda
    Yutaka Tokuda
    Hhiroji Iwata
    Breast Cancer Research and Treatment, 2018, 167 : 81 - 87
  • [30] Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis
    Shimomura, A.
    Niikura, N.
    Fukatsu, Y.
    Sawaki, M.
    Ogiya, R.
    Yasojima, H.
    Fujisawa, T.
    Yamamoto, M.
    Tsuneizumi, M.
    Kitani, A.
    Watanabe, J.
    Matsui, A.
    Takahashi, Y.
    Takashima, S.
    Shien, T.
    Tamura, K.
    Saji, S.
    Masuda, N.
    Tokuda, Y.
    Iwata, H.
    ANNALS OF ONCOLOGY, 2017, 28
12345